Travere Therapeutics, Inc. (Nasdaq: TVTX) today announced that on May 10, 2026, the Compensation Committee of its Board of Directors granted inducement equity grants covering an aggregate of 48,800 shares...
Travere Therapeutics, Inc. (Nasdaq: TVTX) today announced that company management will participate in the following upcoming investor conferences: BofA Securities 2026 Health...
Travere Therapeutics, Inc. (Nasdaq: TVTX) today announced the pricing of its underwritten offering of $475.0 million aggregate principal amount of 0.50% convertible senior notes due 2032 (the “Notes”)....
Travere Therapeutics, Inc. (Nasdaq: TVTX) today announced its intention to offer, subject to market and other conditions, $400 million aggregate principal amount of convertible senior notes due 2032 (the...
FILSPARI achieved record 993 new PSFs for IgAN in the U.S. in the first quarter; U.S. net product sales grew 88% year over year to $105 million FDA approval in FSGS expands...
Barchart Research What to Expect from TVTX Earnings TVTX Generated May 1, 2026 Current Price $44.12 EPS Estimate $$-0.30 Consensus Rating Strong Buy Average Move 4.87% Travere's FSGS Approval Afterglow...
Barchart Research What to Expect from TVTX Earnings TVTX Generated May 1, 2026 Current Price $44.12 EPS Estimate $$-0.30 Consensus Rating Strong Buy Average Move 4.87% Travere's FSGS Approval Afterglow...
Barchart Research What to Expect from TVTX Earnings TVTX Generated May 1, 2026 Current Price $44.12 EPS Estimate $$-0.30 Consensus Rating Strong Buy Average Move 4.87% Travere's FSGS Approval Afterglow...
Travere Therapeutics, Inc. (Nasdaq: TVTX) today announced it will report first quarter 2026 financial results on Monday, May 4, 2026, after the close of the U.S. financial markets. The Company will host...